Saturday, March 8, 2014
Neil Cavuto on Feeling Moved to Tell Viewers: ‘It’s Not Me, It’s The Multiple Sclerosis’
Merck KGaA shores up Rebif defenses to fend off new MS rivals
Merck KGaA's multiple sclerosis treatment Rebif is holding its own. Considering that the German drugmaker's flagship product faces some formidable new competitors--including Biogen Idec's ($BIIB) brand-new powerhouse, Tecfidera--that's not too shabby.
The drug brought in €1.86 billion last year, or about $2.56 billion, a decline of 1.5%, despite what Merck calls "severe competitive pressure" in the U.S. Tecfidera launched last spring, and joining Novartis' ($NVS) Gilenya and Sanofi's ($SNY) Aubagio in the oral MS market. Rebif is an injected treatment, and like other MS injectables, faces bleed-off from patients defecting to the easier-to-take pills.
Merck expects the scuffle for sales to intensify this year, and it's building up its battlements, particularly in the EU. "Several new competitors to our product Rebif are expected to enter the market (in Europe)," the company says in its annual report. "Strategies for defending market share have been launched."
Among those new products are Biogen's Tecfidera, approved in Europe last month, and Sanofi's Lemtrada, which got the nod last fall. Sanofi has some head-to-head data it can tout in its cause. In a head-to-head study between the two drugs, funded by the French company, Lemtrada bested Rebif at reducing relapse rates and slowing disability.
The European onslaught won't be instantaneous, because the tedious process of reimbursement negotiations will make both launches a country-by-country affair. Meanwhile, delays in new product launches could help Rebif's cause, the company notes. And the drug could well benefit from Sanofi's setback on Lemtrada in the U.S. The FDA asked for more safety data, and if new clinical trials are required, that could delay its entry by three years, analysts said at the time.
Play the MS Matching Game: brain games can help exercise your mind
Survey showed strong uptake of the new 40-milligram, thrice-weekly version of Teva's Copaxone, estimating that about 40% of MSers will have switched to it after two years
New warning suggested for Ambien...the same sleeping pill that landed a Kennedy before a jury: says patients shouldn't drive for 8 hours after they take meds like Ambien
$15 Million awarded to former Newark teacher with MS who says district retaliated against her
A Glittering Rock Reunion of 14,300 Fans Becomes the Best of Get-Well Gifts for Guitarist Ronnie Lane
Study: 2014 Multiple Sclerosis Therapeutic Update, UCSF MS Department of Neurology, San Francisco, CA
Study: High prevalence and no latitude gradient of multiple sclerosis in Norway
Study: Supervised exercise training has substantial benefits for MSers, yet 80% of those with MS do not meet recommended levels of moderate-to-vigorous physical activity (MVPA)
"British Health Minister Edwin Poots witnessed first-hand how oxygen therapy can help MSers enjoy a better quality of life"
Illinois lottery game fund multiple sclerosis research
Friday, March 7, 2014
BREAKING NEWS! WARNING: Pfizer Issues Nationwide Recall of Antidepressant Effexor
For Runner With M.S., No Pain While Racing, No Feeling at the Finish (New York Times)
Kayla Montgomery, 18, was found to have multiple sclerosis three years ago. Defying most logic, she has gone on to become one of the fastest young distance runners in the country — one who cannot stay on her feet after crossing the finish line. Because M.S. blocks nerve signals from Montgomery’s legs to her brain, particularly as her body temperature increases, she can move at steady speeds that cause other runners pain she cannot sense, creating the peculiar circumstance in which the symptoms of a disease might confer an athletic advantage.
But intense exercise can also trigger weakness and instability; as Montgomery goes numb in races, she can continue moving forward as if on autopilot, but any disruption, like stopping, makes her lose control.
Click to read more at New York Times
A MSer's story of how she & her Neuro both had problems with Anthem BlueCross getting her MS treatment refilled:
"Worse Than the Mob:Read more »
The Insurance Industry Is Organized Crime"
"......we tried and failed all week to get Anthem to approve her prescription refill. By
My wife’s neurologist is one of the best MS specialists in the city of Boston...He was appalled and astonished by what we had been dealing with, and took it upon himself to deal with Anthem himself…and after five hours on the phone morning, we were frantic; she had one dose left, her MS symptoms were escalating rapidly because she had been rationing her medication for days, and if we didn’t get it done today, there could be no delivery of the medication, and we would be stuck with no medicine until after the weekend, and likely into the middle of the next week, if not beyond. Repeated calls to Anthem resulted in the same lather-rinse-repeat runaround, so in extremis, we reached out to her neurologist in Boston to see if he could help.
Labels: 10 BEST
Doctors’ #1 Source for Healthcare Information: Wikipedia
50% of physicians look up conditions on the site, and some are editing articles themselves to improve the quality of available information
Read more »
Merck KGaA shores up Rebif defenses to fend off new MS rivals
Novartis, Sanofi, Biogen tout new MS drug research
New data is rolling out at the European Committee for Treatment and Research in Multiple Sclerosis annual meeting this week, with the new slate of oral treatments in the spotlight, along with a lineup of older injectables and experimental drugs. So far, one common theme is this: Early treatment equals better results.Read more »
My recent struggles made me realize, you only live life one time
"Innate Immunotherapeutics delivered results from animal studies which further support its novel MIS416 therapy as a candidate to treat Secondary Progressive Multiple "Sclerosis (SPMS)
Oregon Health & Science University today announced the creation of the OHSU Center for Embryonic Cell and Gene Therapy, led by Shoukhrat Mitalipov, Ph.D., a world-renowned leader in embryonic stem cell and gene therapy research
Study: Neglecting data from individuals with MS who exhibit head movement during functional magnetic resonance imaging (fMRI) scanning may bias sampling away from individuals with lower cognitive ability
Study: MiR-126: a novel route for Tysabri (natalizumab) action?
"Dr. Monson has developed a validated method for pre-testing people living with MS to determine if they are a carrier of a unique antibody gene that leads to the disease, thus mitigating the long-standing challenge of diagnosis"
MS trial to explore vitamin D links
Study: Oxygen Cost of Walking in Persons with Multiple Sclerosis: Disability Matters, but Why?
Thursday, March 6, 2014
A SAD BUT IMPORTANT LESSON FOR ALL MSers: "Inquest hears how MSer dropped match or cigarette onto her bed that engulfed her in flames and burnt down her home
This MSer believes marijuana helped put his MS in remission: soon however, Davidson will be forced to destroy the medicine he credits with saving his life
Biogen Idec finished 2013 on a high note, with its highly touted oral multiple sclerosis drug Tecfidera producing nearly $400 million in sales during the fourth quarter
Study Findings from Biogen Idec, Inc. Provide New Insights into Multiple Sclerosis
Slightest change makes myelin come unglued: One common characteristic of diseased myelin is swelling due to MS
OMG of the week: Doctors flee homes after declaring strike
Doctors and Nurses at the Komfo Anokye Teaching Hospital are now fleeing their homes after abandoning their duties last week. The health workers say they fear for their lives after some young men attacked them at the hospital over a missing baby.Read more »
What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?
How Inactivity Change MSer's Brains
One-liners may hint at feelings about health care
Click to read about the study by Dartmouth researchers that looked at the success of punchline jokes on doctors and health systems on Facebook: out of 156 jokes they gauged how popular they were in terms of "likes" and LOL's
RUNNING HELPS ME MANAGE MY MS: Jeanine Parson
Wednesday, March 5, 2014
I'm a mother of 3 young children and here's my horror story of my MS & the new health care law
I was diagnosed in 2012 after a significant episode that attacked both my brain and spinal cord. During this episode, I experienced dizziness, nausea, “brain fog”, tingling, numbness, stiffness from the waist down to my toes, lack of balance, inability to walk and extreme fatigue. I needed help to do the basic functions of life.
TAKEDA ADMITS TO IMPROPERLY MARKETING BLOCKBUSTER DRUG a AFTER DOCTOR POINTS OUT DATA IN AD DIDNT MATCH RESULTS OF CLINICAL STUDY
Study: “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis
Clues To Causes Of Nerve Cell Degeneration in MS Provided By Spasticity Gene Finding
Minn. physicians ponder medical pot: Is marijuana an effective treatment for pain, illness and disease?
Study: MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge
Variables associated with patient activation in persons with multiple sclerosis
Identifying variables associated with patient activation in the multiple sclerosis population could serve to facilitate better multiple sclerosis self-management behaviors. Using a cross-sectional survey design, 199 participants were recruited from a multiple sclerosis center in the Southeastern United States. Depression, multiple sclerosis quality of life, and multiple Sclerosis self-efficacy were all significantly correlated with patient activation. Results of a hierarchical regression indicated that patient activation was significantly related to educational attainment, depression, and self-efficacy but not to quality of life. The results suggest several possible targets for intervention to increase patient activation, including health literacy, depression symptoms, and self-efficacy for multiple sclerosis disease management.
What Vitamin D Dosage Do I need? How Much Sun Do I Need?
Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
Biogen Idec's CEO talks about it's new Tysabri & it's new MS treatments at Health Care Conference (Transcript)
Study: Assessment of cancer risk with β-interferon treatment for multiple sclerosis
OMG OF THE WEEK: Medical treatments harmed nearly a third of nursing home residents, according to a government watchdog report
Tuesday, March 4, 2014
SANOFI SLAPPED WITH $28,000,000 BRIBERY FINE
It turns out the corruption probe in China wasn't Sanofi's only recent bribery investigation.
As Full Disclosure Nears, Doctors’ Pay for Drug Talks Plummets
FREE GUIDE: MANAGING A RELAPSE
VIDEO: MRI Scans and MS
Doctors discuss the increased utilization of magnetic resonance imaging (MRI) scans and its impact in multiple sclerosis
Read more »
MSers need help to take advantage of Obamacare
Despite the significant improvements to our health care system for people with chronic conditions like multiple sclerosis there is still a lot of work to be done to realize the full potential of Obamacare.
Express Scripts stops covering older, commonly used treatments such as Bayer's multiple sclerosis drug Betaseron on clinical, cost-effectiveness grounds
Study: Antiviral drug Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS
Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis
Study: Constraint-induced movement therapy increased neuroplasticity in MS patients according to MRI findings, whereas massage, yoga, and other "complementary/alternative medicine" treatments did not.
Arshiya’s special talent: I used to jump all the way down the steps in Hodge Lee in one leap. I felt like Superman, or rather, Superwoman. That was before I got MS
TEVA'S COPAXONE PATENT IS UP AND ITS DESPERATE TO KEEP PATIENTS & INSURERS
Teva is trying to persuade patients and their doctors to switch from the daily injection to a new, three-times-a-week version! PLUS: trying to get insurers to pay for it!Read more »
DOES THIS NEW STUDY MEAN ANYTHING FOR MS PATIENTS?: "Medical Marijuana: Studies Find No Benefit for RA: Rheumatologists should not currently be recommending the use of medical marijuana to their patients for relief of chronic pain, researchers stated
Rheumatologists should not currently be recommending the use of medical marijuana to their patients for relief of chronic pain, researchers stated. Among the reasons for this advice are acute and chronic risks, a lack of evidence for efficacy, and the absence of data on appropriate dosing, according toMary-Ann Fitzcharles, MD, of McGill University in Montreal, and colleagues.Read more »
4 Things All Doctors Need To Know About Health IT Security
Video: THE SCANDAL THAT ROCKED THE PATIENT SAFETY MOVEMENT BREAK...
Monday, March 3, 2014
CAN CAFFEINE HELP AN MSers MEMORY: Caffeine’s little memory jolt garners a lot of excitement
Air Force Academy's future rests in Lt. Gen. Michelle Johnson steady hands: the institution's first female superintendent, has been tearing down barriers all her life including MS
Senate Passes Casey MS Resolution Ahead of Multiple Sclerosis Awareness Week Inbox
"MS doesn't define us - it's just there"
7 women are suing Doctor & health network for medical negligence, claiming the doctor misdiagnosed them with multiple sclerosis
"My 1st experience as an immunologist diagnosed with MS" by Griselda Zuccarino-Catina, PH.D.
DOCTORS BEDSIDE MANNER: written by a doctor
i make a point of communication with my patient. obviously if he is a child, i use the same measure of effort in communicating with the parents. but few things irritate me more than some or other family member that insists on forcing their way into the fairly personal interaction between patient and the guy that in all likelihood is going to carve him up in the very near future.
Read more »
Immunophenotyping Separates MS Subtypes by Neuroinflammation
What's new in the fight against MS? USA Today
Sunday, March 2, 2014
Another big beast joins the MS Drug fray: ofatumumab phase 2 trial results
"MS used to be a orphan disease. Interferon-beta-1a (Avonex) was licensed by the FDA under the orphan drug legislation. What is an orphan disease? Orphan diseases are rare diseases that only affect a small percentage of the population. Orphan drug acts were put in place to incentivise drug companies to take the risk and develop drugs for these diseases. MS is no longer an orphan disease; sales of DMTs for MS are close to $15billion a year. In the beginning the Pharma companies in the MS space were relatively small, but as the market expanded the big beasts started to arrive; Novartis, Sanofi, Roche and now GSK. GSK is developing ofatumumab for MS; the stunning phase 2 results are presented below."
Study may provide future insights into causes and mechanisms of MS
Using the surface forces apparatus and an atomic force microscope, researchers at UC Santa Barbara have taken a molecular approach to myelin membrane interactions, leading to insights into demyelinating diseases, such as multiple sclerosis.
The next step, according to Jacob Israelachvili, professor at UCSB, is to develop a user-friendly bench-top instrument that could be used in hospitals and clinics to visualize the membranes of certain cells, both healthy and pathological, whose domain structure can be an indicator of the progression of a disease.
Read more »
30% of the 16,651 people who died of an opioid overdose also had taken a benzodiazepine
Working as a full time police officer & living with MS
Here's 5 ways to help ease the pain of winter months
Obamacare Hikes Cost to Patients of Specialty Drugs for MS
The battle of a 6th grader recently diagnosed with MS
Study: Stethoscopes carry more bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), than a physician’s hand
Merck's Rebif is a 3rd major MS drug to be discovered in Israel: The Israeli Connection
Kristen discovers running as way to combat her MS
Cara Therapeutics has exciting new MS drugs in their pipeline
Study: See One, Do One: Watching Action Boosts Brain Volume, Ability
Watching a video demonstration of a simple right-handed activity, such as using a fork or a hammer, appears to affect brain volume and improve the ability of the viewer to perform that task, according to a new study.Read more »
Study: Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection
Saturday, March 1, 2014
We've posted 314 Studies & Stories for you so far this week
News is posted at Midnight and throughout the day 7 days a week!SHARE MSnewsChannel.com WITH YOUR FELLOW DOCTORS AND NURSES
We're building the 12 MS Drug Treatment Channels at the top of this page & hope to finish them by June 1,2014!
SHARE MSnewsChannel.com CLICK THE TINY ENVELOPE BELOW:
FOR DOCTORS ONLY: 15 Smartphone Apps to Improve Your Practice
I am a private practice rheumatologist, not a computer scientist. But I have a special interest in software applications (apps), particularly those that can streamline my workflow.Read more »
Labels: Docs Only
WEEKEND LOL REPORT: Medical School Limiting the Number of Creepy Applicants to Cut Down on Creepy Doctors
Medical school deans across the nation have started to follow Creighton’s lead. “We have been seeing a large number of creepy doctors, and well that has to stop,” Dr. Larry Summers, Dean of Medical School Admissions at Duke University told reporters. “We were arguably the biggest culprits, and we are changing our tune.”
Read more »
Video: 'Dallas Buyers Club' connects with MSers
The book by Charles Fox, "With a Little Help from My Friends: A Love Story" is very similar because Fox had Multiple Sclerosis & fought for more than 30 years to get interferon to treat himself.
The Dallas Buyers Club and Charles Fox's account raises the issue of how drug regulation and in particular the FDA works. It is clear the FDA has a mandate to protect the citizens of the US from harmful drugs, however, the process of drug development is so painfully slow that if you have diseases such as AIDS or MS the delays in getting effective drugs to market means that many people died or became disabled waiting, sometimes in vain, for access to the relevant drugs.
FOR DOCTORS ONLY: Study Companion: Mastering Clinical Concepts in MS Management
Test and improve your mastery of MS management in a new CME/CE activity
Recent advances in disease-modifying and symptomatic therapies for MS are leading to improved outcomes for patients. This interactive, online activity allows you to test your competence across the MS management spectrum:
Read more »
SCANDAL: Research Report Says multiple sclerosis treatment didn’t contain any of its active ingredient
Questcor Pharmaceuticals, an Anaheim-based company already under the cloud of multiple government investigations, now has another, potentially more serious one to add to the list. The U.S. Food and Drug Administration said Thursday it is examining the results of privately funded laboratory tests that show Questcor’s highly lucrative drug, Acthar Gel, contains virtually none of the pig hormone that is purported to be its active ingredient. The drug, which treats a number of autoimmune and inflammatory diseases, sells for $28,000 per vial.
Study: Pill could help humans live longer: The research is published in the journal Cell Reports.
Study: Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes
Pushing the Boundaries of MS Research: The Myelin Repair Foundation
Video: New Research on Multiple Sclerosis from The Doctors
Study: Obesity, contraceptives pills may increase risk of developing MS
Study: Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years
Study: Comparing Face-to-Face and Online Qualitative Research With MSers
Study: Body fluid biomarkers in multiple sclerosis
Study: The good and the bad of neuroinflammation in multiple sclerosis
Friday, February 28, 2014
Multiple sclerosis linked to contraceptive pill: Risk could be up to 50% higher in women who take it
Taking the contraceptive Pill may increase a woman’s chance of developing multiple sclerosis, researchers warn
The risk of MS could be up to 50 per cent higher among women on the Pill, according to a new US study. The findings also show young obese women are at greater risk of the disease, probably because they produce higher levels of a hormone known to regulate appetite.
US researchers identified 305 women who had been diagnosed with MS during a three-year period. Their use of the Pill – mainly a combination of two hormones – was compared with 3,050 women who did not have MS.
Read more »
Study: Pathology of multiple sclerosis
A casual conversation in a hockey locker room prompted a business partnership & research that may lead to new drug that may help MSers
MS LOL OF THE MONTH: Apitherapy -- could therapy based on bee venom sting conventional medicine?
Moody's upgrades Biogen's credit on strong MS drug sales
ABC News video: The Sleep Whisperer Can Help MSers Get to Sleep
Video: New MS Treatment now available in Canada but not the US: more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years. !
Watch this video to see how during an extensive, ongoing clinical development program, 80 per cent of RRMS patients who received two treatment courses of LEMTRADA required no further therapy and 55 per cent remained relapse-free through the first year of the extension study. Unlike other current disease modifying therapies in which stopping treatment usually results in resumed disease activity, LEMTRADA continues to have a durable effect far beyond the two annual treatment courses. In fact, in more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years.
Researchers comparing the blood of 16 healthy people who later developed multiple sclerosis (MS), with the blood of 16 healthy people of the same age and sex who did not develop MS, believe they have found an antibody that could predict the disease before
5 Tips for Managing Stress With MS - CNN
Hippotherapy For Multiple Sclerosis Makes Horse Sense
Gentle yoga an alternative for MSers
Thursday, February 27, 2014
Study: Tobacco smoking and excess mortality in multiple sclerosis: Journal of Neurology, Neurosurgery & Psychiatry
Dang! Richard Pryor Was An Incredible Singer Too? (Take A Look!)
New Patent: Pregnancy hormone combination for treatment of MS: US Patent 8658627 Abstract
A personal story about dealing with family emergencies while having multiple sclerosis
Vitamin D Levels Appear to Be Robust Predictor of MS Progression
30 year old teacher with MS inspires students, wins dream vacation
Read how...Ms. Collins who walks with a cane...asks her students each year to name her cane based on the characters from their books & howshe never stops smiling, being funny, and helps her students see they can overcome any obstacle.”
The Most Radical Innovation to Zippers in Over a Century helps MSers
MSer Fights More than Fires
Most people don't fight multiple sclerosis while running a full-time business and being a volunteer firefighter on the side. But Aimee Lambert, 30 isn't most people.
"I don't like to let things stop me," explains Aimee, who took a break on a recent day, to talk about her life, her disease, her work, and her volunteering. "I can only talk a few minutes," says Aimee, "I've got to get back to work."
Aimee's "work" is running Wags & Whiskers, a pet-grooming business. But, typically, Aimee does her business a bit different than most-she drives a mobile van and comes to the client's house, doing the grooming there. When not grooming animals, Aimee is volunteer firefighter.
Study: Factors associated with accidental falls in MSers
Study: The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis
90% of people with disabilities did as well or better at their jobs compared with other employees: survey shows
Plus...it showed that 86% of this group rated average or better in attendance, and the retention rate was 72% higher. This is why employers should hire people living with episodic disabilities.
"Most people with episodic disabilities are eager and able to continue working, but many cannot do so without reasonable accommodation from their employers," says Stephen Tattle, Acting Executive Director of CWGHR. "At the same time, employers face the negative impacts of losing experienced workers and the high cost of replacing them."
Episodic disabilities are lifelong conditions like multiple sclerosis, arthritis, diabetes, HIV, hepatitis C, chronic fatigue syndrome, migraines, chronic pain, and some forms of cancer and mental illness.
Labels: TOP 100
Receptos released positive results in a mid-stage trial of its Multiple Sclerosis drug — RPC1063
Read how the heads of Receptos developed the blockbuster Rituxan, the first monoclonal antibody drug for cancer, which also found applications in autoimmune diseases...plus Daclizumab which is an injectable treatment for multiple sclerosis
Labels: TOP 100
Wednesday, February 26, 2014
"Yes, I have MS -- my life with multiple sclerosis" by Janice Dean, senior meteorologist for Fox News Channel
Video: Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents
Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with. “Now, until recently that whole idea of risks versus benefits was really about the benefits of the medicine versus the risks of tolerability issues,” said Dr Kantor. “So not of major safety issues.” Self-injectables may be a burden to some, they have a long-term safety profile. Though convenient, newer oral medications have more safety concerns and risks. It is imperative that physicians work with their individual patients to manage risks when using new agents
Obesity at age 20 may be associated with increased risk of MS
Multiple sclerosis shows a "striking" association with obesity at age 20 years that strongly interacts with genetic susceptibility, according to an analysis of data from two case-control studies that examined environmental and genetic risk factors for MS.
Read more »
Pregnancy outcomes in the clinical development program of Gilenyq (fingolimod) in multiple sclerosis
Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation.
Study: Multiple sclerosis progression linked to whole brain atrophy
The progression of disability in patients with multiple sclerosis was associated with whole brain, cortical, and putamen atrophy during the first 5 years after diagnosis, driven chiefly by a greater decline in gray matter than in white matter volume, according to a report published online in Journal of Neurology, Neurosurgery & Psychiatry.
To identify markers of disability progression in MS, researchers assessed 81 patients residing in Southwestern Norway who were diagnosed in 1998 or 2000 and underwent full neurologic assessments and brain MRI at that time, as well as 5 and 10 years later. Patients whose disability progressed, based on the Expanded Disability Status Scale, during follow-up were no different from those whose disability remained stable in demographic factors, MS subtype, or the use or duration of disease-modifying treatment, said Dr. Cecilie Jacobsen of the department of neurology at Stavanger (Norway) University Hospital and the Neuroimaging Analysis Center at the State University of New York at Buffalo, and her associates.
At 5 years, disease progression was associated with significantly greater volume declines in patients with disease than in those without in measurements of the whole brain (–3.8% vs. –2.0%), cortex (–3.4% vs. –1.8%), and putamen (–10.6% vs. –3.8%). However, at 10 years, there was only a nonsignificant trend toward decreased whole brain volume among patients with disease progression. The correlation was much stronger between disability progression and the decline in gray matter volume than it was between disability progression and the decline in white matter volume. "These findings strengthen the increasing evidence that [gray matter] pathology may be playing a crucial role in MS-related disability progression," the investigators wrote (J. Neurol. Neurosurg. Psychiatry 2014 Feb. 19 [doi:10.1136/jnnp-2013-306906]
Playing Video Games Could Help MSers Restore Balance
Read how having multiple sclerosis can leave you feeling off-balance and prone to falls and injury and the steps you can take to preserve mobility
Study: Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS
MS researchers win Thermo Scientific Cellome Award for this Study: A regenerative approach to the treatment of multiple sclerosis
The CCSVI theory that constricted neck veins are to blame for MS has been dealt a fatal blow by a University of B.C.-led study published in the Lancet Tuesday.
Discriminatory Disease Exploring the gender gap in multiple sclerosis
10 year old MSer Lucy Wood had her hair cut off to help raise funds for 2 year old cancer victim, Bradley Lowery
BRAVE 10 year old Lucy Wood may suffer from multiple sclerosis but she never stops thinking of others.
The ten-year-old has needed hospital treatment for the debilitating illness ever since she was five.
But she has still made time to raise money for charity by having her hair chopped off to support poorly youngster Bradley Lowery.
Now, the two of them are best of friends and, like Bradley, Lucy has now been nominated for a Pride of Hartlepool award.
?!?!?! "Potential cure for multiple sclerosis to be tested" from the The Japan Times
Tuesday, February 25, 2014
FREE DOWNLOAD: "Multiple Sclerosis...Sex, intimacy and relationships"
Although sexual difficulties are common among the population as a whole, MS can bring about particular problems for both men and women
Not everyone with MS will experience sexual problems and, as with other MS symptoms, it is impossible to predict who will be affected and how long symptoms may last. There are techniques that can improve communication and understanding, and help you to adapt to new dynamics within your relationships. Many people, both with and without MS, have successful and satisfying relationships despite experiencing sexual difficulties. This booklet covers:
Read more »
Proof that dogs really are MSers' best friends: Meet Amber, the 'wonder-dog' who answers the phone, takes out the laundry and makes the bed
Study: Neurofilament light antibodies in serum reflect response to Tysabri(natalizumab) treatment in multiple sclerosis
Study: Home-based system for physical activity monitoring in patients with multiple sclerosis (Pilot study)
Study: When patient opinion and clinical science are implacably opposed: the view from an MS specialist
Study: Gender and autoimmune comorbidity in multiple sclerosis
HERE'S ANOTHER OF THE MANY ARTICLES THAT SAYS TECFIDERA IS WONDERFUL BUT: NO ONE KNOWS HOW IT WORKS?!?!
Tecfidera is a modified version of a treatment that was originally used to treat the skin disease psoriasis. ‘Nobody is sure exactly how it works,’ explains Belinda Weller, consultant neurologist at the Anne Rowling Regenerative Neurological Clinic in Edinburgh.‘It’s a new approach to treating MS which is believed to help cells in the body defend themselves against the damage caused by MS.’ Read more
Could Sleep Problems Make MSers Fatigue Worse?
Study: Modafinil combined with cognitive training is associated with improved learning in healthy volunteers - A randomised controlled trial
Read more »
Study: Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions
URL: Read how these findings suggest that there are gender differences in the CNS of MS patients that may affect lesion pathogenesis, that is, in males, estrogen synthesis and signaling are induced; whereas in females, progestogen synthesis and signaling are induced plus how hese differences may represent contributing factors to gender differences in the prevalence and course of MS.
Physician Entrepreneurs Are Reinventing Themselves because they believe they may have the next great idea for healthcare
Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis
Is Normal Pressure Hydrocephalus A Component of Multiple Sclerosis Pathology?
Britain's regulatory agency turns down Biogen Idec’s oral MS drug Tecfidera
Monday, February 24, 2014
New book by MSer Yvonne Decelis: It's Not as Bad as it Sounds (my life with MS & Fibro)
Her goal as an author is to educate people on possible ways to improve their quality of life and to let them know they are not alone. She also hopes to help loved ones, friends and colleagues understand things that patients go through day-to-day.Read more »
Yvonne Decelis-Nicholls, Columnist & News Editor, MSnewsChannel.com
I have relapsing remitting Multiple Sclerosis (and Fibromyalgia as well). I was diagnosed with MS in December of 1994 but I am fairly certain I have had it all my life. I was born with a tremor, was sick as a child (constantly) and had a host of problems that MS would explain. I don't think that the kids who bullied me in school would have been kinder to me had they been aware I had a disease but that is something I will never know. I was terrible at all things gym related and I had issues with my shake and my balance that I got made fun of over on a constant basis.
Read more »
THE AMAZING DOCTOR WHO WAS PART OF A TEAM WHO HELPED INVENT COPAXONE & REBIF & IS NOW FOCUSING ON STEM CELLS AT 75
Six months after his 75th birthday, after teaching generations of young graduate and post-doctoral students at the Weizmann Institute of Science and with a wife, four children and 12 grandchildren, one could expect Prof. Michel Revel to sit back and enjoy life. Yet, the Frenchborn, internationally acclaimed molecular geneticist, who invented a major drug to treat multiple sclerosis used around the world and received the Israel Prize, EMET Prize and other major awards, has his eyes fixed on the future.
Read more »
1,500 Participants to Climb 66 Floors at Rock Center Raising Funds for Multiple Sclerosis
The New York City - Southern New York Chapter of the National Multiple Sclerosis Society will host Climb to the Top on , at at 30 Rockefeller Plaza.
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial
MSer Becomes First Disabled Man to Skydive Over Mount Everest
Multiple sclerosis genetics: leaving no stone unturned
First map of core white matter connections reveals that not all brain connections are equally important
Read how these new findings on the brain's network scaffold help inform clinicians about the neurological impacts of MS
Video Discussion: Characterizing Multiple Sclerosis
Click to watch Fred Lublin, MD, define the 4 subtypes of MS: relapsing-remitting MS, secondary-progressive MS, primary-progressive MS, and progressive-relapsing MS and Patricia K. Coyle, MD, joins the discussion and describes the relationship between clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) to MS
Study: Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis
Read how the results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression and how detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients.
Stem Cells Stop the Train of MS Damage in Mice: Neural precursors derived from mature tissues rebuild myelin in mice with EAE
A new guideline on “Assessment and Management of Psychiatric Disorders in Individuals with Multiple Sclerosis” from the American Academy of Neurology was recently published
Study: What are exosomes and how can they be used in multiple sclerosis therapy?
The Consortium of Multiple Sclerosis Centers (CMSC) recently announced that this year’s 28th AnnualMultiple Sclerosis meeting will take place in Dallas, Texas on May 28-31
Neurologist outraged over FDA denial of SA-developed drug Lemtrada and is making a plea to the Food and Drug Administration to reconsider its denial of an investigational treatment for multiple sclerosis.
Click here to watch this video about how Lemtrada has helped the neurologist's patient win the war against MS for 11 years
Sunday, February 23, 2014
Study: AMPYRA IMPROVES WALKING FOR MSers
22 Photo Slideshow: The Medscape Physician Lifestyle Report 2014 reveals both good and bad eating habits among physicians including their favorite diets
Autologous haematopoietic stem cell transplantation is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centers
STUDY: Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. RESULTS: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status
Read more »
Video: Brenda Banwell, MD, Discusses Treatment Options for Pediatric Multiple Sclerosis
Video: Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis
A wheelchair-bound MSer performer has staged a play to highlight her condition at one of London's most well-known venues.
Study: People suffering from schizophrenia face a greater risk of developing autoimmune diseases, such as psoriasis and multiple sclerosis
Plea not to cut beds for MS & Parkinson’s Patients
Green Tea, Blueberry Supplement May Improve Cognition
Dr. Sanjay Gupta: "Keeping track of thinning retinas can help predict multiple sclerosis relapses, in which symptoms recur as isolated flare-ups"
Study found that patients with MS relapses had 42 percent faster retinal thinning than those without relapses. The study’s authors noted that the findings may suggest that retinal thinning occurs faster in patients with more active MS.
Video: What works and what doesn't work for treating migraine?
Click to watch 3 experts talk about effective therapies, including triptans, botulinum toxin, and ergot derivatives.
Biogen Idec hits its first price hurdle for Tecfidera in the EU: Is told that the drug's cost is not justified by its benefits
Thugs Controlled Pill Mill Doctors at Gunpoint, Feds Say
Study: Brief cognitive-behavioral therapy for insomnia (CBTi) can reduce healthcare utilization and costs
Exercise & A New Particle to Fight Multiple Sclerosis and Brain Aging
Eight reasons why Pilates is great exercise for someone with Multiple Sclerosis
Saturday, February 22, 2014
UPDATE: Jody Corey-Bloom, M.D., PH.D Professor of Neurosciences Director of the UC San Diego MS Center University of California, San Diego
"SMOKING MARIJUANA CUTS SPASTICITY & PAIN THAT'S RESISTANT TO CONVENTIONAL TREATMENTS FOR MS PATIENTS"
A difference or two or more points is considered clinically meaningful on the 30-point Ashworth scale which covers mobility of elbows, hips, and knees, report Jody Corey-Bloom, M.D., Ph.D., and colleagues at UCSD. The researchers reported their findings online in CMAJ.
Besides the positive effects on spasticity, pain scores decreased by about 50 percent as well, the researchers reported. “We saw a beneficial effect of smoked cannabis on treatment-resistant spasticity and pain associated with multiple sclerosis among our participants,” Corey-Bloom said.
The findings regarding smoked marijuana support anecdotal evidence from many MS patients who say smoking the herb relieves spasticity, the researchers noted. About 400,000 pepole in the United States have MS.
The body naturally produces cannabinoids, a group of chemicals also found in marijuana. Studies have suggested that the cannabinoid receptors on our cells help regulate muscle spasticity, reports Amy Norton of Reuters.
Read more »
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business.
#1 Glaterimer acetate Teva $4.3 billion
#2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »
Popular Diets: What Docs Eat! What They Need to Know! 12 PHOTO SLIDESHOW
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
"PPMS: A New Hope?" by MS Patient & Ph.D: EMILY WILLINGHAM, PH.D.
Study: A urological challenge: Voiding dysfunction in multiple sclerosis.
This summary provides strategies to help reduce the impact of these symptoms.
Read more »
Study: Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis
Study results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression. Detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients
Neuromyelitis Optics: Once thought of as a variant of multiple sclerosis, neuromyelitis optica is now clearly understood to be a different disease
Data shows treatment inequalities for EU's multiple sclerosis patients
Access to treatment and services varies remarkably for EU citizens diagnosed with multiple sclerosis, depending on which country they live in, according to a survey by the European Multiple Sclerosis Platform (EMSP).
MS researchers find task meaningfulness influences learning and memory
Antibody may be detectable in blood years before multiple sclerosis symptoms appear
MSer Barbara Jordan began dealing with prejudices & she used them to fuel her success.
Clay Walker kicks off State Fair
Firefighters help one of their own to help pay the medical expenses for Jason Van Norman, a firefighter battling Multiple Sclerosis
Natural methods can help MS joint pain relief
Legalized Marijuana: Companies Moving Now To Cash In On Cannabis
Friday, February 21, 2014
Study: TEARS OF MSers CONTAIN HIGH LEVELS OF AN INFLAMATION-INHIBITING PROTIEN THAT MIGHT SERVE AS A DIAGNOSTIC BIOMARKER FOR MS
A safe and simple biomarker would be easier on both patients and doctors and possibly enable earlier diagnosis without
requiring expensive MRI imaging, and invasive lumbar punctures.
Cindy Salvisberg and colleagues at the Medical University Center of the University of Geneva, Switzerland, have uncovered a new MS biomarker that can be safely collected from patients’ tears. Their study appeared online ahead of print in Proteomics Clinical Applications (Salvisberg et al., 2014).
Read more »
Study: Remyelination: Are Exosomes Containing microRNA the Answer? Naturally produced exosomes with miRNA led to increased myelination in vitro and in vivo
Read how today’s treatments for multiple sclerosis aim squarely at the immune system, not the sheath of myelin that insulates and nourishes axons. Eventually, MS destroys that protective layer formed by oligodendrocytes for good. But that could soon change with a new therapeutic strategy to remyelinate axons...
Study: Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS
Read how the drug ganciclovir may quell inflammation in the MS brain by a mechanism distinct from the antiviral activity for which it is known, and without compromising immunity in the periphery, according to a study published in the Journal of Experimental Medicine (Ding et al., 2014).
Merck went through a serious downsizing after its key multiple sclerosis drug candidate failed two years ago, slashing 1000's of jobs and closing its Swiss R&D operation and some plants
The drugmaker could use some new candidates since its setback from the failure of its once-high-profile MS therapy. Stimuvax, a cancer vaccine, also came up short in Phase III, although Merck will test it in a subgroup of patients. Garijo told Bloomberg his company is also developing a "super Erbitux" from a product it licensed from Symphogen. read more
‘Female Viagra’ finds difficult path at FDA
Click to read more about how: as usual, women are being overlooked. The Food and Drug Administration has approved 24 drugs for the treatment of male sexual dysfunction. For women, that number is zero.
Study: Multiple Sclerosis Affects Women More than Men - link to an online video
Study: Comprehensive Eye Exams Can Help Identify Some Chronic Conditions, May Lead to Improved Health
Study: Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomized trial
Study: Naturally Occurring Packets Show Promise for Protecting Nerve Fibers in the Brain
Click to read how researchers are now exploring how to craft exosomes into a treatment for multiple sclerosis. The lab-grown exosomes stimulated myelin production in a sample of rat brain tissue intended to simulate multiple sclerosis damage, returning myelin levels to 77 percent of normal
Go to Older News